The Pharmacological Treatment of Chronic Obstructive Pulmonary Disease. - Wikidata - awgldk - TriplyDB

The Pharmacological Treatment of Chronic Obstructive Pulmonary Disease.

The Pharmacological Treatment of Chronic Obstructive Pulmonary Disease.

http://www.wikidata.org/entity/Q37128138

about

A Belgian survey on the diagnosis of asthma-COPD overlap syndrome.Maintenance therapy in COPD: time to phase out ICS and switch to the new LAMA/LABA inhalers?Pulmonary Rehabilitation and Exercise Training in Chronic Obstructive Pulmonary Disease.

P2860

Q37649862-E2E80899-668B-429F-A20F-332774A3551B Q39426952-3A6D1CBB-9475-4E3D-8ABF-91D2ABA4C1D9 Q55375269-949728AF-4252-4334-B95F-2F8B855998A2

P2860

The Pharmacological Treatment of Chronic Obstructive Pulmonary Disease.

http://www.wikidata.org/entity/Q37128138

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on May 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

The Pharmacological Treatment of Chronic Obstructive Pulmonary Disease.

@en

The Pharmacological Treatment of Chronic Obstructive Pulmonary Disease.

@nl

type

label

The Pharmacological Treatment of Chronic Obstructive Pulmonary Disease.

@en

The Pharmacological Treatment of Chronic Obstructive Pulmonary Disease.

@nl

prefLabel

The Pharmacological Treatment of Chronic Obstructive Pulmonary Disease.

@en

The Pharmacological Treatment of Chronic Obstructive Pulmonary Disease.

@nl

P1433

Q37128138-F5930646-F08E-40F6-ADAD-E802DDB73313

P1476

Q37128138-C35AE5AA-DC4E-4F70-A876-62D51BB1A795

P2093

Q37128138-0072F4A9-669F-4976-AC08-65C90829B25C

Q37128138-0FF9D833-8813-41EA-AA7B-91A670EC49F1

Q37128138-37B62F85-171C-4B3F-91B3-0AB299C634C5

Q37128138-C2679BD4-7707-4227-86E0-F2EC0CE1130D

Q37128138-E2247A76-04DE-4878-821F-688B1AA33D46

Q37128138-FB5C5AAF-A13E-4B9A-A6EE-BD146A5F316E

P2860

Q37128138-07303447-B87E-4026-A2CB-BD7AAC64E802

Q37128138-080824F6-0D93-482F-92E6-C9AA17FA3867

Q37128138-11F0F923-9173-433F-978B-4A65C21531DE

Q37128138-12D098AA-6CAD-40F0-AC75-69BFD09455CF

Q37128138-136335DF-C57C-4DAF-8CAB-FDECC11020E0

Q37128138-24022FC5-ED86-40EA-A2B4-DC80C8C754EA

Q37128138-3231553D-3FFB-4832-96DE-37D9FD76DB07

Q37128138-51032B08-E06C-4975-95A4-BAE3953B874B

Q37128138-510EF45E-6F7A-4C10-A302-082A1A0B9B65

Q37128138-522521B8-B67F-48D4-9519-6A3878F506AC

P304

Q37128138-3A4A3628-BACF-401D-B443-B556C0AD8F0F

P31

Q37128138-86958547-69d9-4e5e-845c-15ed6b2b09cf

Q37128138-A6B966EC-2691-476F-B758-290D075769D0

Q37128138-b270ce57-fcc0-41c1-b7c0-8fce01940bfa

P356

Q37128138-E8A700F2-DA54-42EE-BA07-E6C2F7C3BAB3

P433

Q37128138-3F630F3C-63B8-493F-82D4-56C7EDBFC225

P478

Q37128138-F385D64D-3767-4E6B-8776-1F565E2AA8A1

P577

Q37128138-117F064B-E2AB-49D6-AE13-65C6435FF19A

P698

Q37128138-14BA99BD-D147-4040-B99D-4BD24B3965AF

P921

Q37128138-30001EA6-D645-45A1-8D59-D84C78AACD26

Q37128138-F8546DE4-E6BD-4851-9E93-A0194C42194A

P932

Q37128138-6FE7F012-3A84-4A99-815D-59B5A14F1132

P356

ARZTEBL.2016.0311

P1433

Deutsches Ärzteblatt international

P1476

The Pharmacological Treatment of Chronic Obstructive Pulmonary Disease.

@en

P2093

Adrian Gillissen

http://www.w3.org/2001/XMLSchema#string

Christian Gessner

http://www.w3.org/2001/XMLSchema#string

Klaus Kroegel

http://www.w3.org/2001/XMLSchema#string

Martin Khlhäufl

http://www.w3.org/2001/XMLSchema#string

Peter Haidl

http://www.w3.org/2001/XMLSchema#string

Thomas Voshaar

http://www.w3.org/2001/XMLSchema#string

P2860

Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial

The efficacy and safety of triple inhaled treatment in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis using Bayesian methods

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials.

Overtreatment of COPD with inhaled corticosteroids--implications for safety and costs: cross-sectional observational study.

Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial.

Sputum eosinophilia can predict responsiveness to inhaled corticosteroid treatment in patients with overlap syndrome of COPD and asthma.

Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial.

One-year treatment with mometasone furoate in chronic obstructive pulmonary disease

Safety of long-acting beta-agonists in stable COPD: a systematic review.

P304

311-316

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3238/ARZTEBL.2016.0311

http://www.w3.org/2001/XMLSchema#string

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

113

http://www.w3.org/2001/XMLSchema#string

P577

2016-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27215595

http://www.w3.org/2001/XMLSchema#string

P921

chronic obstructive pulmonary disease

P932

4961886

http://www.w3.org/2001/XMLSchema#string